

Central Serous Chorioretinopathy After Vestibular Schwannoma Treatment: A Case Report

Gamze MADEN^{1*}, Seyma Gülcenur ÖZTURAN¹, Akın ÇAKIR¹, Selim BÖLÜKBASI¹, Mehmet Egemen KARATAŞ² and Mustafa Nuri ELÇİOĞLU¹

¹Department of Ophthalmology, Okmeydani Training and Research Hospital, Istanbul, Turkey

²Department of Ophthalmology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

***Corresponding Author:** Gamze Maden, Department of Ophthalmology, Okmeydani Training and Research Hospital, Istanbul, Turkey.

Received: December 28, 2017; Published: January 20, 2018

Abstract

Central serous chorioretinopathy (CSR) is a disease that typically occurs in young males which is characterized with central serous detachments that regress spontaneously. Most of the cases recover spontaneously in a few weeks, however in some cases it can become chronic, permanent or last as long as six months or longer. The 54-year-old-patient with Vestibular Schwannoma (VS) who had consulted to Istanbul Okmeydani Research and Training Hospital Ophthalmology Clinic with the complaint of decreased vision in the right eye has been diagnosed with chronic CSR. Since it is well-known that corticosteroid usage is an important risk factor for CSR, it has been considered interesting for etiological assignation that the case had received Cyber Knife treatment due to VS during the same period. It should be taken into consideration that secondary CSR can develop with steroid treatment which is used with CyberKnife treatment that is practiced currently and increasingly for the treatment of many tumor types.

Keywords: Schwannoma; CyberKnife; Central Serous Chorioretinopathy; Corticosteroid


Volume 1 Issue 5 January 2018

© All Copy Rights Reserved by Gamze Maden., et al.

Case Presentation

The 54-year-old-female patient G.Ş. consulted to Istanbul Okmeydani Research and Training Hospital Ophthalmology Clinic with the complaint of decreased vision in the right eye. Based on the case's history, it was revealed that 2, 5 years ago the patient had received CyberKnife treatment due to VS and visual complaints started after that. During the ophthalmologic examination the observations turned out to be as following: right vision 1 mps uncorrected, no increase with correction, left vision 1.0, right-left eye anterior segment normal, right eye's fundus observation retinal pigment epithelium (RPE) change in the macula, left eye's fundus observation normal. Optic Coherence Tomography (OCT) and Fundus Fluorescein Angiography (FFA) were recommended for the case. With the OCT's taken, RPE change in the right eye, window defect in the back poles of the right and the left eye were observed and no active leakage was noticed in the late phases. Right and left peripheral retinas were observed as natural. FFA images proved to be coherent with chronic central serous retinopathy. As the anamnesis of the case's was dwelt into further, it was discovered that the patient had used 32 mg of oral methylprednisolone daily and it was cut down digressively until completely given up. Chronic CSR was linked to the aforementioned situation. Since the disease wasn't in an active phase no treatment was offered and a follow-up was recommended.

Citation: Gamze Maden., et al. "Central Serous Chorioretinopathy After Vestibular Schwannoma Treatment: A Case Report". *Ophthalmology and Vision Science* 1.5 (2018): 183-185.



Discussion

Vestibular Schwannomas are benign tumors, however they can cause mass growth and serious secondary morbidity [1]. CyberKnife® (Accuray Inc., Sunnyvale, CA) which was developed recently has a significant place with a variety of tumors's treatment [2]. CyberKnifeunit is a robotic radiosurgery system which delivers radiation to the target with a real time image guidance system. This treatment has been fractionated to decrease the damage to the neighbouring critical structures [3]. This treatment is also used for intraocular melanomas. And when it is used for this purpose neovascular glaucoma, cataract, vitreous hemorrhage, optic neuropathy are the main complications which occur [4-5]. Yet no ophthalmic complications have been reported relating to its usage for VS.

The CSR's with our patient is thought to have developed as secondary to the long term systemic corticosteroid usage. Because even though maculopathy is one of CyberKnife's treatment's well-known side effects, aforementioned side-effect is known to appear with ocular tumor treatment. There is no maculopathy case with intracranial tumor treatment which has been reported. The long term systemic corticosteroid usage in the etiology supports our claim as well. However the lack of evidence regarding the development of maculopathy after intracranial CyberKnife treatment and the concurrent appliance of systemic corticosteroid treatment may prevent us from clarifying the etiology. Treatment results to be evaluated from a broader range of cases can help us confirm the etiology.

References

1. Pannullo SC., et al. "Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease". *Journal of Neuro-Oncology* 103.1 (2011): 1-17.
2. Satar B and Arslan HH. "New Approaches for Treatment of Vestibular Schwannoma". *Turkiye Klinikleri Journal of Ear Nose and Throat-Special Topics* 6.3 (2013): 85-100.
3. Mueller AJ., et al. "Stereotactic radiosurgery of large uveal melanomas with Gamma Knife". *Ophthalmology* 107.7 (2000): 1381-1387.
4. Modorati G., et al. "Gamma Knife radiosurgery for uveal melanoma: 12 years of experience". *British Journal of Ophthalmology* 93.1 (2009): 40-44.
5. Modorati G., et al. "Gamma Knife radiosurgery for uveal melanoma: 12 years of experience". *British Journal of Ophthalmology* 93.1 (2009): 40-44.

**Submit your next manuscript to Scientia Ricerca Open Access
and benefit from:**

- Prompt and fair double blinded peer review from experts
- Fast and efficient online submission
- Timely updates about your manuscript status
- Sharing Option: Social Networking Enabled
- Open access: articles available free online
- Global attainment for your research

Submit your manuscript at:

<https://scientiaricerca.com/submit-manuscript.php>